Paper Details

  1. Home
  2. Paper Details

Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.

Author: Aoyagi-ScharberMika, BellSean M, BullensSherry, BuntingStuart, CastilloSianna, Dvorak-EwellMelita, KrejciPavel, LorgetFlorence, O'NeillCharles A, PengJeff, RimoinDavid L, WendtDaniel J, WilcoxWilliam R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study developed modified variants of human CNP, resistant to proteolytic degradation, that retain the ability to stimulate signaling downstream of the CNP receptor.
Paper Details　
Original Abstract of the Article :
Achondroplasia (ACH), the most common form of human dwarfism, is caused by an activating autosomal dominant mutation in the fibroblast growth factor receptor-3 gene. Genetic overexpression of C-type natriuretic peptide (CNP), a positive regulator of endochondral bone growth, prevents dwarfism in mou...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1124/jpet.114.218560

データ提供：米国国立医学図書館（NLM）

A New Approach to Treating Dwarfism

The field of [research field] is continuously seeking new ways to address complex medical challenges. This study explores a promising treatment for achondroplasia, a form of dwarfism, using a modified variant of C-type natriuretic peptide (CNP). The researchers developed a CNP variant resistant to degradation by neutral endopeptidase and found that [main discovery]. This breakthrough opens doors for developing new therapies to improve the lives of those living with achondroplasia.

Hope for a Taller Future

This research provides hope for patients with achondroplasia, demonstrating that [specific results] can be achieved with the modified CNP variant. This development suggests that a future with more effective treatment options for this condition is within reach.

The Promise of Personalized Medicine

This study highlights the potential of personalized medicine, where treatments are tailored to the specific needs of each patient. By developing innovative therapies like this modified CNP variant, we can address the unique challenges faced by individuals with achondroplasia and create a more equitable future for all.

Dr.Camel's Conclusion

This study is a testament to the resilience of human spirit and the boundless potential of medical research. Like the desert that endures harsh conditions yet harbors life, scientists are finding ways to overcome the challenges of achondroplasia, offering hope for a taller, brighter future.

Date :
  1. Date Completed 2015-05-09
  2. Date Revised 2021-12-24
Further Info :

Pubmed ID

25650377

DOI: Digital Object Identifier

10.1124/jpet.114.218560

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.